AZN Analysis & News - AstraZeneca Group plc | Seeking Alpha

AZN

AstraZeneca Group plc | NYSE

1d 5d 1m 6m 1y 5y 10Y MAX Advanced Chart

52wk high:41.38

52wk low:31.99

EPS (FWD):1.87

PE (FWD):21.78

Div Rate (FWD):1.76

Yield (FWD):4.30%

Market Cap:$103.8B

Volume:

Analysis

Cancer Research Highlight: PARP Inhibition Sets A New Benchmark For Ovarian Cancer
Zach Hartman•Wed, Oct. 24•10 Comments
AstraZeneca Lynparza Scores A Big Win At ESMO
Terry Chrisomalis•Tue, Oct. 23•12 Comments
AstraZeneca Receives FDA Approval For Rare B-Cell Lymphoma Drug Lumoxiti
Terry Chrisomalis•Tue, Sep. 18
AstraZeneca Looks To Its Asthma Drug For Blockbuster Potential
Terry Chrisomalis•Mon, Sep. 10
Your Daily Scoop: Anifrolumab Flunks, Aquestive Approved, Vertex's CRISPR Trial In Germany
Avisol Capital Partners•Mon, Sep. 3•2 Comments
How The Diabetes Market May Soon Cross Over Into Parkinson's
Christiana Friedman•Mon, Jul. 30•9 Comments
AstraZeneca's Late-Stage Study Win Reinforces Its Hold On Particular Segment Of Lung Cancer Market
Terry Chrisomalis•Tue, May 29•1 Comment
AstraZeneca Sees A Phase 3 Flop, But Not All Is Lost
Terry Chrisomalis•Mon, May 14•2 Comments
How Will This Unexpected War For First-Line Lung End?
Zach Hartman•Mon, Apr. 16•14 Comments
AstraZeneca Looks To Prove Itself In The Type 2 Diabetes Market
Terry Chrisomalis•Thu, Mar. 22•10 Comments
I've Sold AstraZeneca Because Of Its Rising Share Price And Weak Results
John Kingham•Fri, Mar. 9•20 Comments
AstraZeneca Scores FDA First, Time To Capitalize Before Competitors Roll In
Terry Chrisomalis•Mon, Feb. 19•7 Comments
Biotech Analysis Central Pharma News: Galectin's Failure, Revance's Positive Results, Novo Nordisk's FDA Win
Terry Chrisomalis•Dec. 6, 2017•28 Comments
Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets 2 FDA Approvals, GW Pharmaceuticals' Price Target Lowered
Avisol Capital Partners•Nov. 15, 2017•3 Comments
Your Daily Pharma Scoop: AstraZeneca's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
Avisol Capital Partners•Oct. 18, 2017•6 Comments

News

AstraZeneca's Farxiga shows CV benefit in large-scale study
SA News•Today, 7:09 AM•3 Comments
FDA accepts AstraZeneca's marketing application for expanded use for Lynparza
SA News•Today, 6:55 AM
Mirati's mocetinostat + AstraZeneca's Imfinzi show positive effect in mid-stage lung cancer study
SA News•Fri, Nov. 9
Britain's cost watchdog for NHS not on board with AstraZeneca's Lynparza
SA News•Fri, Nov. 9•5 Comments
AstraZeneca Group plc (AZN) CEO Pascal Soriot on Q3 2018 Results - Earnings Call Transcript
SA Transcripts•Thu, Nov. 8
AstraZeneca chief stands firm behind $40B in sales by 2023; shares up 4%
SA News•Thu, Nov. 8•1 Comment
AstraZeneca Group plc 2018 Q3 - Results - Earnings Call Slides
SA Transcripts•Thu, Nov. 8
AstraZeneca Q3 revenues down 14%
SA News•Thu, Nov. 8
AstraZeneca beats by $0.27, misses on revenue
SA News•Thu, Nov. 8•3 Comments
Bavarian Nordic launches Phase 1/2 study of prime/boost vaccine CV301 in colorectal and pancreatic cancers
SA News•Fri, Nov. 2•1 Comment
Advaxis bails on Phase 1/2 study of AXAL + Imfinzi; may tweak design of Phase 3 trial of AXAL monotherapy to accelerate data readout; shares down 6% premarket
SA News•Fri, Nov. 2•10 Comments
FDA OKs genetic test to inform on drug metabolism
SA News•Thu, Nov. 1•10 Comments
FDA OKs Merck's Keytruda + chemo for first-line lung cancer
SA News•Tue, Oct. 30•6 Comments
Eagle Pharma's formulation of Faslodex flunks bioequivalence study; shares down 4% premarket
SA News•Tue, Oct. 30
Trump mulling tieing U.S. drug prices to Europe's
SA News•Fri, Oct. 26•298 Comments

More From Our Partners

AstraZeneca's (AZN) Q3 Earnings Beat, New Drugs Drive Sales
at Zacks.com (Thu, 10:38AM)
AstraZeneca returns to sales growth, led by cancer medicines
at CNBC (Thu, 2:26AM)
Astrazeneca Q3 Earnings Preview
at Benzinga (Wed, 1:29PM)
The Zacks Analyst Blog Highlights: AstraZeneca, salesforce, Mastercard, Lam Research and Koninklijke
at Zacks.com (Oct 19, 2018)
Top Analyst Reports for AstraZeneca, Salesforce & Mastercard
at Zacks.com (Oct 18, 2018)